Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex in mild cognitive impairment of Alzheimer type or early Alzheimer's disease
2016-004169-18Phase 2Terminated
- Sponsor
- CIBERNED
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease (4 arms), sponsored by CIBERNED. Primary endpoint: Treatment-emergent adverse events. Started Dec 2016; status: terminated.
02
Drugs
cannabidiol
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on 2016-004169-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004169-18.